. 2023 Sep 22;23(2):316–329. doi: 10.17998/jlc.2023.09.04

Table 3.

Completed clinical trials of combining immune checkpoint inhibitors with locoregional therapies in advanced HCC

Drug and treatment	Phase	Setting	Result	ClinicalTrials.gov identifier
Tremelimumab and RFA/TACE⁵²	I/II	Second-line	PR, 26.3%; median TTP, 7.4 months; median OS, 12.3 months	NCT01853618
Pembrolizumab/nivolumab and thermal ablation⁶²	II	Second-line	ORR, 24%; median PFS, 5 months; median TTP, 6.1 months; OS, 16.9 months	NCT03939975
Nivolumab and ⁹⁰Y radioembolization⁷⁰	II	First-line	ORR, 30.6%; DCR, 58.3%; median PFS, 4.6 months; median OS, 15.1 months; Grade 3/4 TRAEs, 11%	NCT03033446
Nivolumab and SIRT⁹⁵	II	First-line	ORR, 41.5%; median TTP, 8.8 months; median OS, 20.9 months	NCT03380130

HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; PR, partial response, TTP, time to tumor progression; OS, overall survival; ORR, objective response rate; PFS, progression-free survival; DCR, disease control rate; TRAEs, treatment-related adverse events; SIRT, selective internal radiation therapy.